Travere Therapeutics, Inc.TVTXNASDAQ
Loading
SG&A Expense Growth AcceleratingAccelerating
Percentile Rank64
3Y CAGR-21.1%
5Y CAGR+39.1%
Year-over-Year Change
Year-over-year SG&A expense growth
3Y CAGR
-21.1%/yr
Annual compound
5Y CAGR
+39.1%/yr
Recent deceleration
Percentile
P64
Within normal range
vs 5Y Ago
5.2x
Strong expansion
Streak
1 yr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| 2025 | 27.67% |
| 2024 | -0.54% |
| 2023 | 34.44% |
| 2022 | 56.41% |
| 2021 | -7.01% |
| 2020 | 5.31% |
| 2019 | 24.41% |
| 2018 | -0.29% |
| 2017 | 6.06% |
| 2016 | 23.23% |